| Year |
Citation |
Score |
| 2019 |
Houts AC, Olufade T, Shenolikar R, Walker MS, Schwartzberg LS. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings. Cancer Treatment and Research Communications. 19: 100121. PMID 30785027 DOI: 10.1016/J.Ctarc.2019.100121 |
0.319 |
|
| 2018 |
Houts A, Olufade T, Shenolikar R, Walker. Abstract P4-09-15: Real-world clinical outcomes in BRCA-positive metastatic breast cancer patients treated in the community oncology setting Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P4-09-15 |
0.353 |
|
| 2017 |
Houts AC, Ogale S, Sommer N, Satram-Hoang S, Walker MS. Treatment Patterns and Outcomes in Patients with KRAS Wild-Type Metastatic Colorectal Cancer Treated in First Line with Bevacizumab- or Cetuximab-Containing Regimens. Journal of Gastrointestinal Cancer. PMID 29168112 DOI: 10.1007/S12029-017-0027-6 |
0.332 |
|
| 2017 |
Houts AC, Ogale S, Zafar Y, Hubbard JM, Satram-Hoang S, Sommer N, Walker MS. Progression-Free Survival in Patients Receiving Chemotherapy Alone (C) or Chemotherapy with Bevacizumab (CB) for First-Line Treatment of KRAS Mutant Metastatic Colorectal Cancer in Community Oncology Settings. Journal of Gastrointestinal Cancer. PMID 29058260 DOI: 10.1007/S12029-017-0017-8 |
0.354 |
|
| 2016 |
Walker MS, Pohl GM, Houts AC, Peltz G, Miller PJ, Schwartzberg LS, Stepanski EJ, Marciniak M. Analysis of the psychological impact of cancer-related symptoms on patients with non-small cell lung cancer. Psycho-Oncology. PMID 26790987 DOI: 10.1002/Pon.4071 |
0.341 |
|
| 2016 |
Houts AC, Ogale S, Sommer N, Walker MS. Treatment patterns and outcomes in patients with KRAS wild type (WT) metastatic colorectal cancer (mCRC) treated in first line with bevacizumab (B) or cetuximab (C) containing regimens. Journal of Clinical Oncology. 34: 550-550. DOI: 10.1200/Jco.2016.34.4_Suppl.550 |
0.332 |
|
| 2015 |
Walker MS, Cong Z, Knopf KB, Aggarwal SK, Kerr J, Houts AC. Real world impact of treatment-induced peripheral neuropathy (TIPN) on patient reported outcomes (PROs) in patients with multiple myeloma (MM) in the United States. Journal of Clinical Oncology. 33. DOI: 10.1200/Jco.2015.33.15_Suppl.E19531 |
0.324 |
|
| 2014 |
Walker MS, Masaquel AS, Kerr J, Lalla D, Abidoye O, Houts AC, Schwartzberg LS. Early treatment discontinuation and switching in first-line metastatic breast cancer: the role of patient-reported symptom burden. Breast Cancer Research and Treatment. 144: 673-81. PMID 24596047 DOI: 10.1007/S10549-014-2892-Z |
0.39 |
|
| 2014 |
Monberg MJ, Houts AC, Walker MS, Bonifacio G. Observational study of treatment patterns among patients initiating first-line treatment for chronic lymphocytic leukemia in the U.S. community oncology setting. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E18023 |
0.316 |
|
| 2013 |
Freiden Y, Thul A, Houts AC. Reduction in chemotherapy administered at the end of life (CAEOL) through quality improvement processes in a large community oncology clinic: The West Clinic experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 159. PMID 28136385 DOI: 10.1200/Jco.2013.31.31_Suppl.159 |
0.312 |
|
| 2013 |
Walker MS, Miller PJ, Namjoshi M, Houts AC, Stepanski EJ, Schwartzberg LS. Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases. Journal of Medical Economics. 16: 179-89. PMID 23043593 DOI: 10.3111/13696998.2012.737883 |
0.336 |
|
| 2013 |
Stepanski EJ, Reyes C, Walker MS, Satram-Hoang S, Leon L, Wojtowicz-Praga S, Miller PJ, Houts AC, Schwartzberg LS. The association of rash severity with overall survival: findings from patients receiving erlotinib for pancreatic cancer in the community setting. Pancreas. 42: 32-6. PMID 22699203 DOI: 10.1097/Mpa.0B013E318254F19A |
0.339 |
|
| 2013 |
Walker MS, Schwartzberg LS, Chen DM, Ramanan DD, Houts AC, Reyes C. Treatment Patterns and Clinical Characteristics of Patients with Advanced Basal Cell Carcinoma in the Community Oncology Setting Journal of Cancer Therapy. 4: 24-31. DOI: 10.4236/Jct.2013.46A1004 |
0.336 |
|
| 2013 |
Schwartzberg LS, Tauer KW, Hermann RC, Nikolinakos PG, Houts AC. Phase I/II study of neoadjuvant carboplatin, eribulin mesylate, and trastuzumab (ECH) for operable HER2 positive (HER2+) breast cancer. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps659 |
0.318 |
|
| 2012 |
Walker M, Lalla D, Houts A, Schwartzberg L. P-0056 Treatment Patterns and Outcomes in Metastatic Gastric Cancer in The Community Oncology Setting Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)30263-5 |
0.353 |
|
| 2011 |
Walker MS, Stepanski EJ, Reyes C, Satram-Hoang S, Houts AC, Schwartzberg LS. Symptom Burden and Quality of Life in Patients with Follicular Lymphoma undergoing Maintenance Treatment with Rituximab Compared with Observation. Therapeutic Advances in Hematology. 2: 129-39. PMID 23556084 DOI: 10.1177/2040620711407675 |
0.353 |
|
| 2011 |
Olsen JP, Baldwin S, Houts AC. The Patient Care Monitor-Neutropenia Index: development, reliability, and validity of a measure for chemotherapy-induced neutropenia. Oncology Nursing Forum. 38: 360-7. PMID 21531686 DOI: 10.1188/11.Onf.360-367 |
0.314 |
|
| 2010 |
Houts AC, Benn L, Lalla D, Solari PG, Walker MS, Stepanski EJ, Schwartzberg LS. Testing procedures and reasons why HER2-positive breast cancer patients did not receive trastuzumab in the adjuvant setting. Journal of Clinical Oncology. 28. DOI: 10.1200/Jco.2010.28.15_Suppl.E11072 |
0.331 |
|
| 2010 |
Houts A, Lalla D, Walker, Stepanski E, Brammer M, Doan J, Schwartzberg L. Abstract P5-12-04: Symptom Burden Declines When Breast Cancer Patients Treated with Adjuvant Trastuzumab/Combination Chemotherapy Regimens Enter Trastuzumab Monotherapy Follow-Up Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P5-12-04 |
0.367 |
|
| 2009 |
Walker M, Peltz G, Houts A, Pohl G, Schwartzberg L, Stepanski E, Marciniak M. Psychosocial impact of cancer-related symptoms among patients with lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6621. PMID 27961795 DOI: 10.1200/Jco.2009.27.15_Suppl.6621 |
0.327 |
|
| 2009 |
Stepanski EJ, Walker MS, Schwartzberg LS, Blakely LJ, Ong JC, Houts AC. The relation of trouble sleeping, depressed mood, pain, and fatigue in patients with cancer. Journal of Clinical Sleep Medicine : Jcsm : Official Publication of the American Academy of Sleep Medicine. 5: 132-6. PMID 19968046 DOI: 10.5664/Jcsm.27441 |
0.333 |
|
| 2009 |
Stepanski EJ, Houts AC, Schwartzberg LS, Walker MS, Reyes CM, Blakely J. Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden. Clinical Lung Cancer. 10: 426-32. PMID 19900861 DOI: 10.3816/Clc.2009.N.080 |
0.341 |
|
| 2009 |
Schwartzberg LS, Cobb P, Senecal F, Henry D, Kulig K, Walker MS, Houts AC, Stepanski EJ. Initial treatment and changes in adjuvant endocrine therapy for early stage breast cancer. Breast (Edinburgh, Scotland). 18: 78-83. PMID 19342237 DOI: 10.1016/J.Breast.2009.01.002 |
0.382 |
|
| 2009 |
Schwartzberg LS, Cobb P, Walker MS, Stepanski EJ, Houts AC. Patient and practice impact of capecitabine compared to taxanes in first-/second-line chemotherapy for metastatic breast cancer. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 17: 1081-8. PMID 19148686 DOI: 10.1007/S00520-008-0558-2 |
0.374 |
|
| 2009 |
Schwartzberg LS, Stepanski EJ, Walker MS, Mathias S, Houts AC, Fortner BV. Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 17: 91-8. PMID 18592276 DOI: 10.1007/S00520-008-0474-5 |
0.302 |
|
| 2008 |
Moore K, Johnson G, Fortner BV, Houts AC. The AIM Higher Initiative: new procedures implemented for assessment, information, and management of chemotherapy toxicities in community oncology clinics. Clinical Journal of Oncology Nursing. 12: 229-38. PMID 18390459 DOI: 10.1188/08.Cjon.229-238 |
0.313 |
|
| 2007 |
Fortner BV, Schwartzberg LS, Stepanski EJ, Houts AC. Symptom Burden for Patients with Metastatic Colorectal Cancer Treated with First-Line FOLFOX or FOLFIRI with and Without Bevacizumab in the Community Setting. Supportive Cancer Therapy. 4: 233-40. PMID 18632522 DOI: 10.3816/Sct.2007.N.020 |
0.391 |
|
| 2006 |
Fortner BV, Houts AC. Greater physical and psychological symptom burden in patients with grade 3/4 chemotherapy-induced neutropenia. Supportive Cancer Therapy. 3: 173-7. PMID 18632492 DOI: 10.3816/Sct.2006.N.015 |
0.366 |
|
| 2006 |
Houts AC, Loh GA, Fortner BV, Kallich JD. Patient and caregiver time burden associated with anaemia treatment in different patient populations. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 14: 1195-204. PMID 16670851 DOI: 10.1007/S00520-006-0075-0 |
0.348 |
|
| 2006 |
Fortner B, Baldwin S, Schwartzberg L, Houts AC. Validation of the Cancer Care Monitor items for physical symptoms and treatment side effects using expert oncology nurse evaluation. Journal of Pain and Symptom Management. 31: 207-14. PMID 16563315 DOI: 10.1016/J.Jpainsymman.2005.07.009 |
0.311 |
|
| 2005 |
Fortner BV, Tauer KW, Okon T, Houts AC, Schwartzberg LS. Experiencing neutropenia: quality of life interviews with adult cancer patients. Bmc Nursing. 4: 4. PMID 16004611 DOI: 10.1186/1472-6955-4-4 |
0.365 |
|
| 2005 |
Fortner BV, Schwartzberg L, Tauer K, Houts AC, Hackett J, Stolshek BS. Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 13: 522-8. PMID 15678345 DOI: 10.1007/S00520-004-0757-4 |
0.312 |
|
| 2005 |
Schwartzberg L, Houts AC, Fortner BV. Mild anemia is associated with greater symptom burden (SB) and reduced quality of life (QoL) in cancer patients Journal of Clinical Oncology. 23: 8123-8123. DOI: 10.1200/Jco.2005.23.16_Suppl.8123 |
0.34 |
|
| 2004 |
Schwartzberg LS, Fortner BV, Houts AC. Clinical Significance of Symptom Burden and Quality of Life Decrement in Cancer Patients with Mild Anemia. Blood. 104: 5305-5305. DOI: 10.1182/Blood.V104.11.5305.5305 |
0.369 |
|
| 2003 |
Fortner B, Okon T, Schwartzberg L, Tauer K, Houts AC. The Cancer Care Monitor: psychometric content evaluation and pilot testing of a computer administered system for symptom screening and quality of life in adult cancer patients. Journal of Pain and Symptom Management. 26: 1077-92. PMID 14654260 DOI: 10.1016/J.Jpainsymman.2003.04.003 |
0.312 |
|
| 2000 |
Houts AC. Commentary: Treatments for Enuresis: Criteria, Mechanisms, and Health Care Policy Journal of Pediatric Psychology. 25: 219-224. DOI: 10.1093/Jpepsy/25.4.219 |
0.307 |
|
| 1994 |
Houts AC, Berman JS, Abramson H. Effectiveness of Psychological and Pharmacological Treatments for Nocturnal Enuresis. Journal of Consulting and Clinical Psychology. 62: 737-745. PMID 7962877 DOI: 10.1037//0022-006X.62.4.737 |
0.313 |
|
| Show low-probability matches. |